Analysis of new funds. Inveready and Asabys Partners with Banco Sabadell.

20/06/2018
Diego Gutiérrez
Analysis of new funds. Inveready and Asabys Partners with Banco Sabadell.

We analyse the new funds created in Spain in the biotechnology sector during the first half of 2018. In this case, we will study the company Inveready and the alliance between Asabys Partners and Banco Sabadell.

Get in touch with our experts.

We analyse the new funds created in Spain in the biotechnology sector during the first half of 2018. In this case, we will study the company Inveready and the alliance between Asabys Partners and Banco Sabadell.

Inveready

Inveready Technology Investment Group, a Catalan venture capital firm, is a venture capital firm specialising in providing value to early-stage technology companies. According to ASCRI it is one of the leading funds in Spain and in 2017 they were awarded the prize for the best asset management firm in Spain. With six investment funds. Inveready invests in technology companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 80 leading portfolio companies in their respective markets.

Inveready has six investment vehicles with €92 million under management. The funds have invested in more than 80 companies since 2008.

Since we are analysing the new funds that have emerged within the biotech sector, it is worth noting that the average investment in Catalan companies belonging to this sector in 2017 was €3.4M.

With this year's fund, it would be the third investment vehicle in the biotech sector. The fund, called Biotech III, would be the Barcelona-based fund manager's ninth and would have a size of €25m.

CORPORATE FINANCE EXPERTS

Asabys Partners with Banco Sabadell

Asabys Partners, based in Barcelona, is a professional investment firm that works closely with entrepreneurs to build healthcare and innovation companies with technologies and products designed to transform people's lives and provide disruptive solutions to today's healthcare challenges. It specialises in biotech, medtech and healthcare innovation start-ups.

Asabys has recently signed a partnership with Banco Sabadell to launch its first specialised health sciences vehicle, Sabadell Asabys Health Innovation Fund, with a target size of €60M to invest in early stage drug development companies, medical devices and digital applications in Spain, the UK and Israel.

It is worth noting that Banco Sabadell's participation is proof of its continued commitment to investing in the healthcare sector, acting as a benchmark investor in this fund, along with Asabys, recently launched by Sanfeliu, former co-founder/partner of Ysios Capital.

 

Other new funds in the biotech sector

CompanyInverterCountryAmountDate
Abac TherapeuticsCaixa Capital Risk

Pontifax

Global Health Science Fund

Debiopharm Innovation Fund

 

Spain16M€15/02/2018
BDi BiotechnologyInveready

Dyadic International

Spain3,9M€4/01/2018
BionureAlta Life ScienceUSA. USA.4M€17/05/2018
ProteodesignCaixa Capital Risk

Business Angels

Spain1,7M€28/02/2018

Other posts that may interest you

https://techma.bakertilly.es/nuevos-fondos-en-marzo-arta-black-toro-nekko-benavent-trea-direct-lending/

https://techma.bakertilly.es/nuevos-fondos-febrero-nexxus-torreal-towerbrook-peninsula-providence/

https://techma.bakertilly.es/nuevos-fondos-miura-inveready-capzanine/

If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.

If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.

Lastest news

The State of Technology M&A in Spain | October 2026 analysis

En octubre de 2026 hubo 37 operaciones de M&A tecnológico en España: 16 fueron adquisiciones corporativas, inversiones de private equity, fusiones o tomas de participación, y 21 fueron rondas de venture capital. El 62,2% de las operaciones (23 de 37) fueron...

Webinar | How much does your business depend on you?

IMPORTANT INFORMATION: Registration for and participation in the webinars are completely anonymous to third parties. If, for a month, you were unable to have a say in important decisions, what would happen in your company? Your company can grow, be profitable and have good...

Notable technology M&A deals in Spain | September 2026 Analysis

Technology M&A in Spain totalled 61 identified transactions by the end of September 2026, the highest figure in the monthly series we have been publishing since May. Of these, 41 were acquisitions, private equity investments, asset purchases, joint ventures or takeovers...

Baker Tilly advises Invelon on the acquisition of byAR

In September 2026, Invelon, a Spanish technology company specialising in virtual, augmented and mixed reality, completed the acquisition of a majority stake in byAR, a Portuguese company specialising in museum exhibitions and the development of spaces...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?